Erschienen in:
28.07.2020 | ASO Author Reflections
ASO Author Reflections: Prognostication in Early- and Advanced-Stage Small Bowel Adenocarcinomas
verfasst von:
Alessandro Vanoli, MD, PhD, Antonio Di Sabatino, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
Small bowel adenocarcinomas (SBAs) are rare and poorly investigated cancers. Therefore, for a long time, therapeutic approaches for these neoplasms have been mainly extrapolated from colorectal cancer studies. Compelling evidence that SBA is a distinct entity now exists, leading the National Comprehensive Cancer Network (NCCN) to recently publish clinical practice guidelines specific for SBA.
1 Although clear data are still lacking, patients with stage II SBAs having high-risk features (pT4, positive resection margins, or a low number of lymph nodes harvested) may benefit from adjuvant chemotherapy. NCCN guidelines do not recommend adjuvant chemotherapy in stage II SBAs in case of mismatch repair deficiency (MMR-d), although the impact of this tumor phenotype on patient prognosis is still unclear.
1,
2 …